Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 673.50
Bid: 674.50
Ask: 675.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.074%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

1 Feb 2013 07:00

null

Tate & Lyle issues the following interim management statement covering the period from 1 October 2012 to 31 December 2012.

OPERATING PERFORMANCE - CONTINUING OPERATIONS

Group adjusted profit before tax1 for the third quarter was broadly in line with our expectations before the impact of exchange rate movements. As expected, adjusted profit before tax was lower than the comparative period as a result of the step change in fixed costs associated with our business transformation initiatives2.

Within Speciality Food Ingredients, we achieved good sales growth with volume growth ahead of the wider speciality food ingredients market. In starch-based speciality ingredients, we achieved good sales growth with volume growth in all regions. In high intensity sweeteners, while we saw a return towards more normal sucralose volume growth and expect this to continue in the final quarter, the level of growth was not as strong as anticipated in November and we now expect sucralose volumes for the full year to be slightly lower than last year. In Food Systems, sales were broadly in line with the comparative period on lower volumes. Operating profit3 for the Speciality Food Ingredients division for the full year is now expected to be broadly in line with the prior year.

Within Bulk Ingredients, overall demand for North American liquid sweeteners was solid during the third quarter. In Europe, margins for liquid sweeteners were broadly in line with the prior year period. The markets for industrial starches in both Europe and the US were relatively stable while the environment for US ethanol continued to be challenging.

Corn and co-products

Corn supplies in the US and Europe remained tight and with the latest projections from the USDA for the stocks-to-use ratio at 5.3%, prices are expected to remain high with some volatility over the coming months until the new harvest.

As announced in November 2012, we have taken a number of steps to mitigate the impact of aflatoxin, a fungus caused by the unusually hot and dry conditions last summer. The impact of aflatoxin from the new harvest corn was felt particularly in the third quarter while we implemented a number of actions including adjustments to our corn sourcing programme.

We expect a further small increase in net corn costs in the final quarter of the financial year and estimate the impact of aflatoxin will be to reduce operating profit by around £7 million for the full year. We will continue to take action to manage the risks posed by aflatoxin during the first half of next financial year up to the new harvest.

BALANCE SHEET AND WORKING CAPITAL

Net debt at 31 December 2012 was £395 million. In light of continuing tight market conditions in both the US and Europe, we continue to hold high corn inventories for security of supply. As usual, we have paid for a significant amount of this corn in January, and at higher prices than the prior year. As a result, and based on current corn prices and exchange rates4, we currently anticipate that this will drive a net cash outflow in the final quarter of the financial year.

CUSTOMER CONTRACTING

The 2013 calendar year sweetener pricing round in North America for the Bulk Ingredients business is now substantially complete. As in the previous year, this pricing round has been conducted against the backdrop of materially higher corn costs.

In North America, after recovering these higher input costs, we achieved a modest increase in corn sweetener unit margins across our sweetener customers reflecting a continuation of high levels of industry capacity utilisation. Bulk Ingredients sweetener volumes are expected to be broadly in line with calendar year 2012.

In Europe, we continue to contract over shorter periods to partially mitigate corn cost volatility. Despite sugar prices remaining high, sweetener margins are expected to be lower as a result of higher corn costs.

OUTLOOK

The Group has made a solid start to the final quarter. Despite facing a number of headwinds and before the impact of exchange rate movements, we expect to make modest progress this financial year.

Note 1 Continuing operations only. Before exceptional items, amortisation of intangible assets acquired through business combinations and excluding the impact of post-retirement benefit plans from net finance expense

Note 2 Restart of the McIntosh facility; investment in global shared services and IS/IT system; development of Commercial and Food Innovation Centre in Chicago

Note 3 Before exceptional items, amortisation of intangible assets acquired through business combinations

Note 4 At 30 January 2013 the US corn price (March 2013 contract) was US$7.40 per bushel and the US$/£ exchange rate was 1.58

END

A conference call will be held today at 8.00am GMT, hosted by Javed Ahmed, Chief Executive and Tim Lodge, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Participant dial in number: +44 (0) 1452 555 566 (UK freephone 0800 694 0257)

Conference ID: 93466130

Replay dial in number: +44 (0) 1452 550 000 (UK freephone 0800 953 1533)

Replay passcode: 93466130#

A replay of this call will be available from four hours after the end of the live call until 15 February 2013.

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7500 100 320

Andrew Lorenz, FTI Consulting

Tel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641807

Copyright Business Wire 2013

Date   Source Headline
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.